Provision of Antioxidant Therapy in Hemodialysis (PATH) Study
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Studies have shown that end stage renal disease (ESRD) patients have higher levels of blood
markers which their body makes in response to increased stress and injury. An increase in
these markers have been shown to be related to cardiovascular disease and death in ESRD
patients. This study will examine whether antioxidant therapy (Vitamin E and alpha lipoic
acid) may decrease these markers.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborator:
Fresenius Medical Care North America
Treatments:
alpha-Tocopherol Antioxidants Thioctic Acid Tocopherols Tocotrienols Vitamin E Vitamins